

# Peter G Smith

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7219550/publications.pdf>

Version: 2024-02-01

104  
papers

6,498  
citations

66343

42  
h-index

74163

75  
g-index

110  
all docs

110  
docs citations

110  
times ranked

8006  
citing authors

#	ARTICLE	IF	CITATIONS
1	Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. <i>Lancet, The</i> , 2022, 399, 924-944.	13.7	752
2	Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials. <i>Clinical Infectious Diseases</i> , 2014, 58, 470-480.	5.8	749
3	Randomised vaccine trial of single dose of killed <i>Leishmania major</i> plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. <i>Lancet, The</i> , 1998, 351, 1540-1543.	13.7	213
4	MMR vaccination and pervasive developmental disorders: a case-control study. <i>Lancet, The</i> , 2004, 364, 963-969.	13.7	203
5	Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. <i>Journal of Infectious Diseases</i> , 2020, 221, 1752-1756.	4.0	186
6	First generation leishmaniasis vaccines: A review of field efficacy trials. <i>Vaccine</i> , 2008, 26, 6759-6767.	3.8	153
7	Variability of Infectious Aerosols Produced during Coughing by Patients with Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 450-457.	5.6	132
8	A randomised, double-blind, controlled trial of a killed <i>L. major</i> vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. <i>Vaccine</i> , 1999, 17, 466-472.	3.8	131
9	Validation of the diagnosis of autism in general practitioner records. <i>BMC Public Health</i> , 2004, 4, 5.	2.9	123
10	Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis – A meta-analysis. <i>Vaccine</i> , 2009, 27, 4747-4753.	3.8	121
11	Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. <i>Lancet Infectious Diseases, The</i> , 2019, 19, e31-e38.	9.1	120
12	Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e709.	3.0	114
13	Bovine spongiform encephalopathy (BSE) and its epidemiology. <i>British Medical Bulletin</i> , 2003, 66, 185-198.	6.9	110
14	Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. <i>Vaccine</i> , 2021, 39, 4013-4024.	3.8	110
15	Predictability of the UK Variant Creutzfeldt-Jakob Disease Epidemic. <i>Science</i> , 2001, 294, 1729-1731.	12.6	109
16	Risk factors for variant Creutzfeldt-Jakob disease: A case-control study. <i>Annals of Neurology</i> , 2006, 59, 111-120.	5.3	100
17	The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field. <i>Clinical Infectious Diseases</i> , 2016, 62, 69-74.	5.8	84
18	Combined Analysis of Mortality in Three United Kingdom Nuclear Industry Workforces, 1946-1988. <i>Radiation Research</i> , 1994, 138, 224.	1.5	79

#	ARTICLE	IF	CITATIONS
19	Obstacles to conducting epidemiological research in the UK general population. <i>BMJ: British Medical Journal</i> , 2004, 329, 277-279.	2.3	79
20	Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. <i>Vaccine</i> , 2017, 35, 3295-3302.	3.8	77
21	Fetal death and congenital malformation in babies born to nuclear industry employees: report from the nuclear industry family study. <i>Lancet, The</i> , 2000, 356, 1293-1299.	13.7	75
22	Evaluation of diagnostic tests for infectious diseases: general principles. <i>Nature Reviews Microbiology</i> , 2010, 8, S16-S28.	28.6	74
23	WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016. <i>Vaccine</i> , 2019, 37, 7307-7314.	3.8	74
24	Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2613.	3.0	71
25	Tuberculosis in developing countries and methods for its control. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1990, 84, 739-744.	1.8	70
26	Rate and Amplification of Drug Resistance among Previously Treated Patients with Tuberculosis in Kampala, Uganda. <i>Clinical Infectious Diseases</i> , 2008, 47, 1126-1134.	5.8	63
27	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. <i>New England Journal of Medicine</i> , 2020, 382, 1366-1369.	27.0	63
28	Attempted Suicide as Language: An Empirical Study. <i>British Journal of Psychiatry</i> , 1970, 116, 465-473.	2.8	57
29	Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. <i>Expert Review of Vaccines</i> , 2009, 8, 705-716.	4.4	56
30	The inheritance of translocations in man: data from families ascertained through a balanced heterozygote. <i>Annals of Human Genetics</i> , 1970, 34, 119-136.	0.8	55
31	Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. <i>Vaccine</i> , 2020, 38, 2435-2448.	3.8	54
32	Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy. <i>Vaccine</i> , 2019, 37, 7372-7380.	3.8	53
33	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. <i>Vaccine</i> , 2018, 36, 3411-3417.	3.8	52
34	Risk factors for sporadic Creutzfeldt-Jakob disease. <i>Annals of Neurology</i> , 2008, 63, 347-354.	5.3	51
35	Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala, Uganda: A Prospective Cohort Study. <i>PLoS Medicine</i> , 2011, 8, e1000427.	8.4	49
36	Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 638-646.	3.4	49

#	ARTICLE	IF	CITATIONS
37	Structure, function and five basic needs of the global health research system. <i>Journal of Global Health</i> , 2016, 6, 010508.	2.7	48
38	Cancer in children of nuclear industry employees: report on children aged under 25 years from nuclear industry family study. <i>BMJ: British Medical Journal</i> , 1999, 318, 1443-1450.	2.3	46
39	Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. <i>Vaccine</i> , 2017, 35, 5535-5542.	3.8	46
40	Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. <i>Vaccine</i> , 2019, 37, 7394-7395.	3.8	46
41	Placebo use in vaccine trials: Recommendations of a WHO expert panel. <i>Vaccine</i> , 2014, 32, 4708-4712.	3.8	45
42	Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. <i>Health Technology Assessment</i> , 2017, 21, 1-54.	2.8	45
43	Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. <i>Vaccine</i> , 2016, 34, 2865-2869.	3.8	43
44	Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group. <i>Vaccine</i> , 2021, 39, 633-640.	3.8	42
45	The duration of protection of school-aged BCG vaccination in England: a population-based case-control study. <i>International Journal of Epidemiology</i> , 2018, 47, 193-201.	1.9	41
46	Clinical characteristics, predictors, and performance of case definition—Interim results from the WHO global respiratory syncytial virus surveillance pilot. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 647-657.	3.4	40
47	Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2007, 6, 1.	3.8	39
48	WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report. <i>Vaccine</i> , 2019, 37, 7381-7390.	3.8	39
49	Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. <i>Vaccine</i> , 2013, 31, 2603-2609.	3.8	37
50	The Incubation Period of Kuru. <i>Epidemiology</i> , 2002, 13, 402-408.	2.7	36
51	Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. <i>Malaria Journal</i> , 2015, 14, 160.	2.3	36
52	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. <i>Vaccine</i> , 2019, 37, 3190-3198.	3.8	35
53	A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology. <i>BMC Public Health</i> , 2001, 1, 2.	2.9	32
54	Antiretroviral treatment in resource-poor settings: public health research priorities. <i>Tropical Medicine and International Health</i> , 2005, 10, 295-299.	2.3	32

#	ARTICLE	IF	CITATIONS
55	Rate of first recorded diagnosis of autism and other pervasive developmental disorders in United Kingdom general practice, 1988 to 2001. <i>BMC Medicine</i> , 2004, 2, 39.	5.5	31
56	Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. <i>Vaccine</i> , 2017, 35, 3303-3308.	3.8	31
57	Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance—opportunities and challenges. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 622-629.	3.4	31
58	Concepts of herd protection and immunity. <i>Procedia in Vaccinology</i> , 2010, 2, 134-139.	0.4	30
59	The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study. <i>Emerging Themes in Epidemiology</i> , 2015, 12, 1.	2.7	30
60	Choices in vaccine trial design in epidemics of emerging infections. <i>PLoS Medicine</i> , 2018, 15, e1002632.	8.4	29
61	Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia. <i>International Journal of Epidemiology</i> , 2003, 32, 430-436.	1.9	27
62	Social and Environmental Influences on Child Mortality in Brazil: Logistic Regression Analysis of Data from Census Files. <i>Journal of Biosocial Science</i> , 1986, 18, 87-102.	1.2	26
63	A Cluster-Randomised Trial to Compare Home-Based with Health Facility-Based Antiretroviral Treatment in Uganda: Study Design and Baseline Findings. <i>Open AIDS Journal</i> , 2007, 1, 21-27.	0.5	26
64	A study of measles virus and canine distemper virus antibodies, and of childhood infections in multiple sclerosis patients and controls. <i>Journal of the Neurological Sciences</i> , 1982, 56, 1-10.	0.6	25
65	Multiple sclerosis and dog ownership. <i>Journal of the Neurological Sciences</i> , 1982, 55, 359-367.	0.6	25
66	Epidemiological studies of the “non-specific effects” of vaccines: I “ data collection in observational studies. <i>Tropical Medicine and International Health</i> , 2009, 14, 969-976.	2.3	25
67	Treatment Outcomes of New Tuberculosis Patients Hospitalized in Kampala, Uganda: A Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e90614.	2.5	24
68	Vaccine-attributable severe dengue in the Philippines. <i>Lancet</i> , The, 2019, 394, 2151-2152.	13.7	23
69	Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. <i>Wellcome Open Research</i> , 2019, 4, 165.	1.8	23
70	The epidemics of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: current status and future prospects. <i>Bulletin of the World Health Organization</i> , 2003, 81, 123-30.	3.3	22
71	Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation?. <i>Vaccine</i> , 1999, 18, 633-640.	3.8	20
72	Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 615-621.	3.4	20

#	ARTICLE	IF	CITATIONS
73	Integrating health services for HIV infection, diabetes and hypertension in sub-Saharan Africa: a cohort study. <i>BMJ Open</i> , 2021, 11, e053412.	1.9	20
74	WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use. <i>Vaccine</i> , 2022, 40, 3506-3510.	3.8	20
75	Sex ratio of nuclear industry employees' children. <i>Lancet, The</i> , 2001, 357, 1589-1591.	13.7	19
76	Evaluation of diagnostic tests for infectious diseases: general principles. <i>Nature Reviews Microbiology</i> , 2007, 5, S21-S31.	28.6	18
77	Ethics of HIV trials. <i>Lancet, The</i> , 1997, 350, 1546.	13.7	17
78	Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014–2015 outbreak. <i>Clinical Trials</i> , 2016, 13, 13-21.	1.6	17
79	The predictability of the epidemic of variant Creutzfeldt-Jakob disease by back-calculation methods. <i>Statistical Methods in Medical Research</i> , 2003, 12, 203-220.	1.5	16
80	Sensitivity and negative predictive value for a rapid dengue test. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 465-466.	9.1	16
81	Evaluation of diagnostic tests for infectious diseases: general principles. <i>Nature Reviews Microbiology</i> , 2008, 6, S16-S28.	28.6	14
82	Sharing clinical trial data. <i>Lancet, The</i> , 2016, 387, 2287.	13.7	13
83	Comparison of rapid tests for detection of rifampicin-resistant <i>Mycobacterium tuberculosis</i> in Kampala, Uganda. <i>BMC Infectious Diseases</i> , 2009, 9, 139.	2.9	12
84	Guidance on the evaluation of <i>Plasmodium vivax</i> vaccines in populations exposed to natural infection. <i>Vaccine</i> , 2009, 27, 5633-5643.	3.8	12
85	Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. <i>Vaccine</i> , 2011, 29, 3686-3694.	3.8	12
86	Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection. <i>Vaccine</i> , 2021, 39, 4391-4398.	3.8	12
87	Evaluation of adverse effects of vaccines: the case-control approach. <i>Vaccine</i> , 2002, 20, 2611-2617.	3.8	11
88	Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review. <i>Malaria Journal</i> , 2009, 8, 23.	2.3	10
89	Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 66.	1.6	10
90	Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa. <i>BMJ Global Health</i> , 2020, 5, e002193.	4.7	10

#	ARTICLE	IF	CITATIONS
91	Drug misuse, tobacco smoking, alcohol and other social determinants of tuberculosis in UK-born adults in England: a community-based case-control study. <i>Scientific Reports</i> , 2020, 10, 5639.	3.3	9
92	Exercise electrocardiogram tests in manual workers with and without antibodies to <i>Trypanosoma cruzi</i> : a population-based study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1990, 84, 787-791.	1.8	8
93	Making sense of health estimates. <i>Lancet, The</i> , 2015, 385, 1377-1379.	13.7	8
94	The nuclear industry family study: linkage of occupational exposures to reproduction and child health. <i>BMJ: British Medical Journal</i> , 1999, 318, 1453-1454.	2.3	6
95	Response to Cioffi. <i>Journal of Infectious Diseases</i> , 2020, 222, 169-170.	4.0	6
96	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. <i>Vaccine</i> , 2022, 40, 3484-3489.	3.8	6
97	Editorial: Scale-up of antiretroviral therapy in sub-Saharan Africa – priorities for public health research. <i>Tropical Medicine and International Health</i> , 2007, 12, 1009-1010.	2.3	5
98	A vaccine against malaria: a substantial step forward. <i>Lancet, The</i> , 2009, 373, 1411-1412.	13.7	5
99	Novel vaccine safety issues and areas that would benefit from further research. <i>BMJ Global Health</i> , 2021, 6, e003814.	4.7	4
100	The 1957 MRC report on leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis. <i>Journal of Radiological Protection</i> , 2007, 27, B3-B14.	1.1	2
101	Response to Dawson et al. <i>Journal of Infectious Diseases</i> , 2020, 222, 516-517.	4.0	2
102	Daan Mulder Memorial Symposium - Introduction. <i>Tropical Medicine and International Health</i> , 2000, 5, A1-A2.	2.3	1
103	Reply to Hasford and to Spinola et al. <i>Journal of Infectious Diseases</i> , 2020, 222, 1574-1575.	4.0	0
104	Integrating HIV, diabetes and hypertension services in Africa: study protocol for a cluster randomised trial in Tanzania and Uganda. <i>BMJ Open</i> , 2021, 11, e047979.	1.9	0